Flavin Financial Services Inc. Acquires Shares of 28,185 Pfizer Inc. (NYSE:PFE)

Flavin Financial Services Inc. bought a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 28,185 shares of the biopharmaceutical company’s stock, valued at approximately $748,000.

Several other hedge funds also recently made changes to their positions in PFE. Swiss National Bank grew its holdings in Pfizer by 0.6% in the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock worth $486,762,000 after purchasing an additional 100,900 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after buying an additional 12,864,343 shares in the last quarter. Empowered Funds LLC lifted its stake in Pfizer by 80.9% during the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock valued at $14,709,000 after acquiring an additional 227,349 shares during the period. Addison Advisors LLC boosted its holdings in shares of Pfizer by 394.2% during the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock valued at $1,512,000 after acquiring an additional 41,668 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of Pfizer by 26.0% during the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after purchasing an additional 639,985 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

NYSE PFE opened at $26.23 on Tuesday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market cap of $148.62 billion, a price-to-earnings ratio of 35.44, a PEG ratio of 0.66 and a beta of 0.64. The company’s 50 day moving average is $26.27 and its two-hundred day moving average is $27.85. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.56%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Analyst Ratings Changes

A number of equities research analysts have commented on PFE shares. Guggenheim cut their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.